Economic Observation Network Shanghai Pharmaceutical has disclosed its mid-term dividend plan and is simultaneously advancing the board of directors' election, new drug research and development, and product pipeline layout.

Dividend related arrangements:
The board of directors of the company has approved a proposal on May 27, 2026, proposing to implement mid-term cash dividends in 2026, with a total dividend amount not less than 10% and not exceeding 30% of the net profit attributable to the parent company. This proposal still needs to be submitted for review at the 2025 annual shareholders' meeting 。

High level elections:
At the same meeting on May 27th, the company nominated candidates for the new board of directors, including executive directors, non-executive directors, and independent directors. This proposal also needs to be submitted to the shareholders' meeting for review 。

Product development progress:
As of the first quarter of 2026, the company's clinical applications have been accepted and a total of 59 new drug pipelines (47 innovative drugs) have entered the subsequent clinical research stage. Among them, the main study of the Phase III clinical trial of B001 project (treatment of optic neuritis and myelitis) has been unblinded, and the Phase III clinical data locking of Shenqi Shirong Pill project has been completed 。

Subsidiary Development:
Subsidiary Shandong Xinyi Pharmaceutical has become the holder of the marketing authorization for trazodone hydrochloride tablets (with a procurement amount of approximately 750 million yuan for mainland hospitals in 2025), which is beneficial for enriching the company's product line 。

The above content is based on publicly available information and does not constitute investment advice.